[Pharmacotherapy of erectile dysfunction].
Shcheplev
P A
PA
Nesterov
S N
SN
Kukharkin
S A
SA
Abdullaev
I A
IA
Sidorov
D V
DV
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000527:Alprostadil / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D010208:Papaverine / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D010208:Papaverine; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000527:Alprostadil; D010646:Phentolamine